Is a single dose of ChAdOx1 nCoV‐19 vaccine (AZD1222) enough for people with prior SARS‐CoV‐2 infection or baseline seropositive status?

•Better IgG responses were observed in baseline seropositive individuals.•Single-dose IgG responses to AZD1222 were better in indviduals who were previously infected with COVID.•One dose may be sufficient for individuals who were previously infected with COVID.

Saved in:
Bibliographic Details
Published in:International journal of infectious diseases 2022-10, Vol.123, p.143-144
Main Authors: Deswal, Vikas, Phogat, Rashmi, Sharma, Pooja, Kataria, Sushila, Soin, Arvinder
Format: Article
Language:English
Subjects:
Short Communication
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Better IgG responses were observed in baseline seropositive individuals.•Single-dose IgG responses to AZD1222 were better in indviduals who were previously infected with COVID.•One dose may be sufficient for individuals who were previously infected with COVID.
ISSN:1201-9712
1878-3511
DOI:10.1016/j.ijid.2022.06.051